Current evidence does not support routine clinical use of GLP-1 medications specifically for alcohol cravings, and patients with alcohol use disorder should be referred to evidence-based treatments including behavioral interventions, mutual support groups, and FDA-approved pharmacotherapies such as naltrexone, acamprosate, and disulfiram
these citations support the educational context only
JAMA Netw open 3(10):e2020836e2020836 Lach-Trifilieff E, Minetti GC, Sheppard K, Ibebunjo C, Feige JN, Hartmann S, Brachat S, Rivet H, Koelbing C, Morvan F (2014) An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy
References DiCiaula, A., Wang, D.Q.H., Portincasa, P